Not at all. Let's remember that Parabolan was sold at 76.5 mg approved for human use, a dose corresponding to 50 mg of trenbolone, similar to the 50 mg of Organon's Deca Durabolin. Do you think it would have been approved if, in trials and during use, potential users (men, women, and children) had experienced the severe side effects associated with trenbolone today? The answer is obvious. On the other hand, let's remember that the production of injectables by a pharmaceutical company doesn't use the same temperature as those who produce raw materials at UGL. Pharmaceutical companies, by having a sterile environment, their production process reduces the rate of oxidation that could occur. That said, even so, since trenbolone is so susceptible to oxidation, it will usually present a variable oxidation rate, which will cause greater or lesser side effects, that is, an increased pulse rate, night sweats, a probable mitochondrial uncoupling effect, greater stimulation of the nervous system, greater neurotoxicity, and greater organ toxicity. It is true that oxidized products can promote lipolysis or energy expenditure due to this overstimulation of the nervous system (increase in strength), but not in terms of their anabolic potential.